Review: SGLT2 inhibitors and aging biology in preclinical and clinical evidence
This review abstract says SGLT2 inhibitors, known for glucose-lowering and cardiorenal protection, may also influence aging pathways; lifespan extension and reduced senescent cells come from preclinical animal studies, not demonstrated human lifespan benefits. [1]
Automatic summary · not editorially reviewed
The key findings
SGLT2 inhibitors block glucose reabsorption in renal proximal tubules and were developed as antidiabetic agents; large trials also showed reduced cardiovascular and renal events in diabetes. [1]
The abstract proposes antiaging mechanisms including calorie-restriction-like metabolic adaptations, less systemic inflammation, better mitochondrial function and reduced senescent cell burden, framed as possibilities. [1]
Multiple preclinical animal studies reportedly showed lifespan extension and less age-related functional decline; the abstract reports no human lifespan outcomes. [1]
The source at a glance
- Study type / format
- Review abstract
- Population / context
- Patients with diabetes, heart failure or chronic kidney disease in cited trials; animal models in preclinical studies; general aging biology discussed in a review.
- Summary based on
- Study abstract
- Original publication
- July 1, 2026
SGLT2 inhibitors: glucose and cardiorenal effects
The abstract explains that SGLT2 inhibitors block glucose reabsorption in the renal proximal tubules, so more glucose leaves in urine. They were developed as antidiabetic agents. Large clinical trials showed they lower blood glucose and also significantly reduce cardiovascular and renal events in patients with diabetes. Later studies found cardiorenal protection in people with heart failure or chronic kidney disease, whether or not they had diabetes.
Supporting source [1]
Antiaging mechanisms proposed in the review
Beyond those established benefits, the abstract says accumulating evidence suggests possible antiaging effects. Proposed mechanisms include metabolic adaptations resembling calorie restriction and ketogenic states, reduced systemic inflammation, improved mitochondrial function and greater cellular resilience against senescence. Recent findings reportedly show that SGLT2 inhibitors can reduce senescent cell burden and modulate the senescence-associated secretory phenotype, raising the possibility of senotherapeutic or even senolytic properties. These are proposed mechanisms, not proven causes of human aging outcomes.
Supporting source [1]
Animal lifespan data and review scope
The abstract states that multiple preclinical studies showed SGLT2 inhibitors extend lifespan and lessen age-related functional decline in animal models. It does not report human lifespan or healthspan outcomes. The authors summarize current insights into molecular and physiological mechanisms by which these drugs may modulate aging biology and discuss their emerging potential to extend health span and prevent age-related diseases. This is a review abstract; the full text was not reviewed, so details of included studies, designs and sample sizes are not available here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Included study designs, sample sizes and follow-up are not reported. Lifespan and functional benefits come from preclinical animal models, and the antiaging mechanisms are proposed, not established causes of human outcomes.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Katsuumi G, Minamino T. · europepmc.org · July 1, 2026